Vivani Medical expands OKV-119 collaboration with Okava to include dogs for metabolic health

Vivani Medical, Inc.

Collaboration expanded to develop OKV-119 (long-acting GLP-1 implant) for dogs for weight management and diabetes.
Over 50% of U.S. dogs are overweight or obese; leaner dogs can live more than two years longer.
OKV-119 leverages NanoPortal technology for six-month+ dosing, mimicking fasting effects to improve insulin sensitivity.
Financial terms not disclosed; partnership minimizes Vivani's costs/risks with upside via milestone payments and royalties.
Expands prior 2019 collaboration that focused on developing OKV-119 for cats.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.